Project Grant K99HL177331
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $161K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding supports research to develop novel synthetic biology strategies that would enable the quantitative and dynamic regulation of growth factors and cytokines produced from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs). The goal...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) aims to determine if cancer directly promotes cardiovascular disease and explore potential therapies. The $1,102,957 award to The Leland Stanford Junior University, commencing on April 15, 2025 and scheduled for completion on January 31, 2032, will fund a multidisciplinary research program across population genetics, cardio-oncology, and translational medicine. The...
- This Project Grant award of $248,999 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Washington University will leverage patient-specific induced pluripotent stem cell (iPSC)-derived cardiac pericytes and endothelial cells to elucidate the molecular and cellular basis of tyrosine kinase inhibitor-induced vascular toxicity (TKI-VT) and discover personalized therapies. The key objectives are to: Characterize sunitinib-induced cytotoxicity...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,246 to The Leland Stanford Junior University (Stanford University) to investigate the molecular mechanisms underlying cardiovascular toxicity induced by the cancer drug carfilzomib. The goal is to elucidate the role of pathogenic alternative splicing events in smooth muscle cells and endothelial cells, using a humanized multiple...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $760,982 to The University of Texas MD Anderson Cancer Center to investigate the role of the GFPT2 enzyme in radiation-induced cardiovascular disease. The project aims to determine the fundamental mechanisms contributing to radiation-induced cardiovascular disease, identify high-risk patients, and establish new treatment approaches. Key objectives...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $161,903 Project Grant to The Leland Stanford Junior University (Stanford University) on January 31, 2025 under the Cardiovascular Diseases Research (CFDA 93.837) program. The project aims to investigate risk stratification and outcomes across the spectrum of immune checkpoint inhibitor (ICI) cardiotoxicity subtypes. Specifically, the study will: (1) retrospectively examine cardiac and oncologic outcomes associated with ICI...
- This $131,085 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a 5-year research project led by Dr. Arianne Caudal at The Leland Stanford Junior University to elucidate the cardiac-protective mechanisms of SGLT2 inhibitors. The project aims to leverage human induced pluripotent stem cell-derived cardiovascular cells, single-cell RNA sequencing, metabolomics, and large-scale drug-protein interaction determination to...
- This $590,283 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop feedback-controlled closed-loop manufacturing processes for differentiating human pluripotent stem cells into cardiomyocytes. The key objectives are to: 1) Identify failure modes in 2D cardiomyocyte differentiation through integrated single-cell transcriptomics and epigenomics, and 2) Develop control strategies to enhance the reproducibility of human...
- This federal Project Grant award of $552,318 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of carbonic anhydrase as a cardioprotective target for mitigating the cardiotoxic effects of anthracycline chemotherapy drugs like doxorubicin. The research leverages human-induced pluripotent stem cell-derived cardiomyocytes to model anthracycline-induced cardiotoxicity and uses CRISPR interference/activation...
- This Project Grant award for $727,710.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to advance understanding of the mechanisms driving arrhythmogenic cardiomyopathy, a genetic heart disease that can cause sudden death in young people. The award supports research at the University of California, San Diego (UCSD) to develop preclinical mouse models exhibiting inflammation and T-cell mediated immune responses as key drivers of this...